Close
  Indian J Med Microbiol
 

Figure 4: Optical coherence tomography showing the evolution of Macular edema secondary to central retinal vein occlusion 4 months after Ozurdex® implant in a 50-year-old patient. (a) Baseline CMT was 796 μm with BCVA of 1.3 LogMar, (b) significant improvement in CMT (204μm) and BCVA (0.2 LogMar) 2 months after the IVT. However, at the 4th month after IVT (c) macular edema subsequently relapsed, CMT increased to 641μm and BCVA decreased to 0.7 LogMar

Figure 4: Optical coherence tomography showing the evolution of Macular edema secondary to central retinal vein occlusion 4 months after Ozurdex® implant in a 50-year-old patient. (a) Baseline CMT was 796 μm with BCVA of 1.3 LogMar, (b) significant improvement in CMT (204μm) and BCVA (0.2 LogMar) 2 months after the IVT. However, at the 4<sup>th</sup> month after IVT (c) macular edema subsequently relapsed, CMT increased to 641μm and BCVA decreased to 0.7 LogMar